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Moderate to severe traumatic brain injury (TBI) is one of the leading causes of acquired
epilepsy. Prophylaxis for seizures is the standard of care for individuals with moderate to
severe injuries at risk for developing seizures, though relatively limited comparative data is
available to guide clinicians in their choice of agents.There have however been experimen-
tal studies which demonstrate potential neuroprotective qualities of levetiracetam after
TBI, and in turn there is hope that eventually such agents may improve neurobehavioral
outcomes post-TBI.This mini-review summarizes the available studies and suggests areas
for future studies.
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INTRODUCTION
Traumatic brain injury (TBI) refers to a spectrum of neurological
injury resulting from external forces applied to the brain that cause
changes in neurological functioning ranging from a brief alteration
of consciousness (known as a mild TBI or concussion) to severe
TBI which is marked by extended periods of coma or altered con-
sciousness (1). The severity of the initial injury is a fairly reliable
predictor of neurobehavioral outcomes, with more severe injuries
likely leading to permanent neurobehavioral impairments (2). For
individuals who survive the acute phase of a moderate to severe
TBI, a period of functional recovery occurs for up to 2 years post-
injury (3). Despite the potential for recovery, those who survive
moderate to severe TBI frequently experience a host of persistent
neurobehavioral symptoms, such as cognitive deficits, difficulties
with social judgment, fatigue, and mood changes (4).
In addition to the permanent neurobehavioral problems that
can result from moderate to severe TBI, 5–20% of patients who
sustain a severe TBI will develop seizures, a phenomenon known as
post-traumatic epilepsy (PTE) (5, 6). Injury characteristics impact
risk for PTE, with 50% of patients sustaining penetrating head
injuries developing seizures, while closed head injuries appear less
likely to develop such complications (7). The presence of visible
contusions, hemorrhages, longer coma duration, and older age all
also increase the risk for PTE (8).
Post-traumatic epilepsy may account for up to 5% of all cases
of epilepsy in general (6). It is unclear which if any neurophysi-
ological markers are most strongly associated with outcomes, as
well as the development of PTE (9, 10), but there is increasing
evidence that PTE is associated with worse functional outcomes
in general (11). Experimental models have revealed that the post-
injury time period is marked by a host of excitatory neurochemical
changes as well as structural brain changes such as cellular loss and
changes in organization which may foster the development of PTE
(12). Therefore, the acute stage presents an opportunity to inter-
vene prophylactically with anti-epileptic medications in hopes of
preventing or limiting seizure activity. Although there remains
debate about whether prevention of seizures in the acute post-
TBI time period actually prevents the development of epilepsy
over longer time periods (13), current guidelines recommend anti-
epileptic drug (AED) use in at risk patients during the first 7 days
post-injury to prevent acute seizures (14).
The choice of AED agent utilized in severe TBI cases has begun
to shift over the years. Because of its availability in intravenous for-
mat and clinical utility, phenytoin (PHT) was historically utilized
for PTE prophylaxis, despite its need for ongoing clinical moni-
toring and potential for serious adverse side effects (15). However,
since levetiracetam (LEV) became available in an intravenous for-
mulation, it has been increasingly utilized because it requires no
loading dose or ongoing monitoring (16). Recent meta-analysis
(17) and clinical data (18) suggest that both agents are equally
effective in preventing post-traumatic seizures during the first
7 days post-injury, though to date no data is available to indicate
the agents ability to prevent PTE.
Although there are encouraging findings for LEV’s use to pre-
vent acute seizures following TBI, the agents impact on neurobe-
havioral outcomes has been relatively unexplored. As noted above,
moderate to severe TBI by itself is associated with a host of neu-
robehavioral symptoms which vary in severity from patient to
patient and evolve over the course of recovery. Memory impair-
ments, difficulties with executive functioning and social regula-
tion, fatigue, depression, and irritability/aggression are common
post-TBI sequelae (4). Given that some of these symptoms have
been associated with AED use in general (19, 20), it is important to
fully understand any potential interactive or additive effects in the
TBI population in an attempt to avoid or mitigate any untoward
clinical outcomes.
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NEUROBEHAVIORAL IMPACTS OF LEV IN POPULATIONS
OTHER THAN TBI
Levetiracetam has proven to be a popular agent in many neurologi-
cal populations, in part because it has been relatively well-tolerated
from a neurobehavioral standpoint. However, a review of the
evidence from epilepsy samples suggests that LEV treatment is
associated with changes in emotional functioning. Specifically,
studies are suggestive of increased aggression and possibly sui-
cidality, especially in individuals with premorbid depression or
behavior problems (21–23). In children, there is some evidence
that LEV use may be particularly associated with untoward behav-
ioral outcomes. Schiemann-Delgado studied LEV in children with
partial onset seizures and found that LEV was associated with
stable cognitive performance versus placebo, but also mild neu-
robehavioral adverse effects, including increased aggression and
irritability (24).
Summarizing the available data, Mbizvo and colleagues sug-
gested that in patients with epilepsy, LEV add on treatment was
associated with increased somnolence, changes in behavior in 23%
of children studied (but few adults), and no significant impact on
cognition (25).
From a neuropsychological standpoint, the medication seems
well-tolerated. In a small (16 subject) but well-designed experi-
ment involving healthy controls, LEV had cognitive and electro-
physiological effects comparable to that of placebo, suggesting
that at least over the short run in healthy subjects, it had lit-
tle adverse neurobehavioral impact (26). LEV may even provide
some cognitive benefit in select populations. For example, LEV
has been associated with improved memory in patients with high
grade gliomas (27, 28). Similarly, in a retrospective review of
patients with a history of intracranial hemorrhage, patients treated
with LEV were discharged home more often, had higher Glasgow
coma scale (GCS) scores, and demonstrated a trend toward better
global cognitive status (defined as oriented and cooperative versus
not) (29).
THE INTERACTION OF LEV AND TBI ON NEUROBEHAVIORAL
OUTCOMES
In contrast to other populations such as epilepsy or general neuro-
surgery patients, the study of the neurobehavioral profile of LEV
in TBI is still in its infancy, with most data culled from recent
efficacy studies. These studies tend to utilize relatively broad self
or caregiver reports of neurobehavioral changes with little formal
cognitive testing or more granular assessments of neurobehavioral
outcomes.
What information is available,based largely on a series of papers
from the same study suggests an increase in fatigue with LEV use
in TBI during the acute phase. Klein et al published data on the
pharmacokinetics of a PHT+ LEV treatment arm and noted that
around 3% of subjects discontinued the LEV secondary to somno-
lence (30). In a follow-up safety study, Klein and colleagues (31)
found approximately 15% of their sample reported fatigue, som-
nolence, and headache, with most of these symptoms reported as
mild in nature.
Pearl and colleagues (32) recently published data specifically
evaluating the pediatric subjects from the aforementioned study,
followed over 2 months and later 2 years. This study included
measures of problematic behavior and depression, and interest-
ingly there was no difference between LEV treated patients and
controls on these measures. However, during active treatment,
LEV patients showed higher rates of headache, fatigue, drowsi-
ness, and irritability. Eighty-five percent of patients complained of
fatigue, but only 5% rated it as severe. One patient had a psychosis
which resolved with LEV discontinuation. While fatigue may be
considered a minor side effect, it may interfere with participation
in brain injury rehabilitation, which in turn could lead to other
untoward outcomes in a TBI population, and this warrants further
investigation. For example, Nair and Kadies (33) published a case
study of an older individual participating in rehabilitation for a
TBI who was having persistent sleep wake cycle disorder and agi-
tation. While these symptoms had been attributed to his TBI, after
removing LEV he gradually resumed a normal sleep wake cycle
and had less agitation which in turn led to better participation in
rehabilitation.
At a more global level, there is some evidence for better neu-
robehavioral outcomes in both the short and long term with
LEV versus PHT. Szarflarski et al (34) studied a group of 52
patients the majority of which suffered a severe TBI in a ran-
domized single-blinded study comparing PHT and LEV. They
included global outcome measures including the disability rat-
ing scale (DRS) and Glasgow outcome scale (GOS), which assess
in a broad way neurobehavioral status. In this study, there was
no difference in seizure outcomes over both short term and long
term outcome, and similar rates of mortality in each group. Side
effect profiles were similar between groups, with LEV patients hav-
ing fewer instances of a decrease in neurological status and fewer
gastrointestinal problems. Most notably, the LEV patients demon-
strated a statistically significant lower (better) score on the DRS
and a higher (better) GOS score than their PHT matched con-
trols. In contrast to these findings though, Jones and colleagues
(35) found similar 3 and 6 months GOS outcomes when compar-
ing PHT and LEV, and noted that their LEV patients had stronger
tendencies to seizure activity on EEG (but no greater increase
in seizures). Thus the potential for an actual neurobehavioral
benefit to LEV use in post-TBI care remains to be definitively
established.
Unfortunately at the time of this writing no studies were found
which specifically evaluated the neurobehavioral impact of LEV
in the chronic phase of the recovery or in individuals who had
developed PTE.
POTENTIAL FOR NOVEL THERAPEUTIC USES
While current work has focused on LEV as a prophylactic agent
for PTE, there is a history of laboratory work as well as clinical
observations suggesting LEV is a neuroprotective agent which may
improve behavioral outcomes even in the absence of seizure activ-
ity. As noted above, LEV use was associated with better cognitive
outcomes in brain tumor patients (27), and one study revealed
LEV to be associated with improved global outcome (including
neurobehavioral functioning) in severe TBI cases (34). Similarly,
in the suspected prodromal phase of Alzheimer’s disease (amnestic
mild cognitive impairment) LEV use was associated with reduction
in hippocampal activity and paradoxically, improved cognition
(36). The authors suggest that increased hippocampal activation
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may be a sign of potentially damaging overactivation of the brain,
and that LEV may reduce this and thus preserve neurons.
Consistent with this finding, in a rat model of TBI involv-
ing controlled cortical impacts, animals treated early with LEV
versus a saline control had improved motor function, increased
exploratory behavior, better preserved hippocampal cells, and
reduced total volume of contusions (37). The authors propose
that despite LEV still not having a fully elucidated mechanism
of action for the prevention of seizures, its ability to upregulate
glutamate transporters may lead to increased neuroprotection as
well as improved anti-epileptic impact. A similar study conducted
by Wang and colleagues (38) demonstrated a similar pattern of
neuroprotective effects that were not present in animals treated
with fosphenytoin. If replicated and extended to humans, such a
finding would support the use of LEV not just to prevent seizures
but also to prevent the secondary damage of excitotoxicity in the
peri-injury period.
DIRECTIONS FOR FUTURE RESEARCH
Studying neurobehavioral phenomena in TBI is a complex
endeavor, given the heterogeneity of initial injury, different recov-
ery courses, and the difficulty of measuring complex phenomena
such as mood,cognition,and behavior. Partialing out the impact of
a medication such as LEV from the disorder itself which can result
in many of the same symptoms will require careful study design.
A well-designed study to evaluate the neurobehavioral impacts of
LEV would have to include control and treatment groups which
are carefully randomized or matched to control for the impact of
variability in initial injury severity, time since injury, and relevant
demographic and other medical factors (for example controlling
for the presence of other neurobehaviorally active drugs such as
anti-depressants and pain medications). Given the difficulty of
relying on self-report in patients with potential impairments in
cognition and self-awareness, multi-modal assessment end points,
including neuropsychological testing and informant ratings will be
necessary to adequately capture the phenomena of interest. Elec-
trophysiological markers may be helpful to quantify the nature
and extent of physiological impact of LEV in this population,
and imaging techniques to quantify the interaction of specific
structural abnormalities and medication effects would also be
intriguing.
While much research remains to be done on establishing the
efficacy or superiority of LEV for seizure prophylaxis post severe
TBI, future studies may also want to move toward studying LEV as
an adjunctive neuroprotective agent. Adding a longitudinal neu-
robehavioral component to an acute LEV vs. placebo or active
control study with more granular neurobehavioral ratings for each
stage of recovery (i.e., time to follow commands in the acute phase,
ranging to neuropsychological evaluations later in the recovery
course) would allow for evaluating LEV as a potential neuropro-
tective agent. Naturalistic studies which look at the subset of a
sample who continue LEV treatment beyond the current 7 days
window may also yield insights into a potential benefit from
this medication. Finally, functional neuroimaging may provide
insight into how LEV alters the functional activation and connec-
tivity of the recovering brain, unlocking the mechanisms into its
neurobehavioral impact.
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